Polypeptide N-acetylgalactosaminyltransferase 4 (readthrough fusion with POC1B) (POC1B-GALNT4)

POC1B-GALNT4 is a naturally occurring readthrough fusion gene that produces protein isoforms combining features of both POC1B (a centriolar protein) and GALNT4 (a member of the polypeptide N-acetylgalactosaminyltransferase family involved in mucin-type O-linked glycosylation)[2][3][1][8]. This glycosylation pathway is essential for the biosynthesis and function of many glycoproteins, and defects are implicated in diverse diseases, including congenital disorders and neurological syndromes[1]. The fusion transcript exists as a minor isoform and is primarily studied for its molecular and genetic characteristics, rather than as a direct drug target.[2][3][5]\n\nNote:\nThe canonical, therapeutically relevant target is Polypeptide N-acetylgalactosaminyltransferase 4 (GALNT4), not the POC1B-GALNT4 readthrough fusion. The fusion’s biological function and significance in pathology remain ill-defined and it should not be used as a canonical drug discovery target name without further validation.

Other names

POC1B-GALNT4POC1B-GALNT4 ReadthroughPolypeptide N-acetylgalactosaminyltransferase 4UDP-GalNAc:Polypeptide N-acetylgalactosaminyltransferase 4Protein-UDP Acetylgalactosaminyltransferase 4GALNT4Polypeptide GalNAc transferase 4GalNAc-T4pp-GaNTase 4

Not applicable; no drugs specifically target this fusion or the underlying enzyme. General mechanisms for glycosyltransferase inhibition (e.g., blocking O-linked glycosylation) are possible but undocumented for this specific fusion.